AAVantgarde announces first patient dosed in First-In-Human Phase 1/2 LUCE-1 study, evaluating AAVB-081 (Dual-AAV) in retinitis pigmentosa related to Usher Syndrome type 1B
16. September 2024 02:00 ET
|
AAVantgarde Bio
AAVantgarde announces first patient dosed in First-In-Human Phase 1/2 LUCE-1 study